Sulindac targets nuclear β-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines by Boon, E M J et al.
Sulindac targets nuclear b-catenin accumulation and Wnt signalling
in adenomas of patients with familial adenomatous polyposis and
in human colorectal cancer cell lines
EMJ Boon
1, JJ Keller
1, TAM Wormhoudt
1, FM Giardiello
2, GJA Offerhaus
1, R van der Neut
1 and ST Pals*,1
1Department of Pathology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands;
2Department
of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
Nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive potential against colorectal carcinomas (CRCs). Inhibition of
cyclooxygenase (COX)-2 underlies part of this effect, although COX-2-independent mechanisms may also exist. Nonsteroidal anti-
inflammatory drugs appear to inhibit the initial stages of the adenoma–carcinoma sequence, suggesting a link to the APC/b-catenin/
TCF pathway (Wnt-signalling pathway). Therefore, the effect of the NSAID sulindac on nuclear (nonphosphorylated) b-catenin and
b-catenin/TCF-mediated transcription was investigated. Nuclear b-catenin expression was assessed in pretreatment colorectal
adenomas and in adenomas after treatment with sulindac from five patients with familial adenomatous polyposis (FAP). Also, the
effect of sulindac sulphide on b-catenin/TCF-mediated transcription was studied. Adenomas of FAP patients collected after treatment
with sulindac for up to 6 months showed less nuclear b-catenin expression compared to pretreatment adenomas of the same
patients. Sulindac sulphide abrogated b-catenin/TCF-mediated transcription in the CRC cell lines DLD1 and SW480, and decreased
the levels of nonphosphorylated b-catenin. As a result, the protein levels of the positively regulated TCF targets Met and cyclin D1
were downregulated after sulindac treatment. This study provides in vivo and in vitro evidence that nuclear b-catenin localisation and
b-catenin/TCF-regulated transcription of target genes can be inhibited by sulindac. The inhibition of Wnt-signalling provides an
explanation for the COX-2-independent mechanism of chemoprevention by NSAIDs.
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Epidemiological data, rodent studies and in vitro experiments have
demonstrated that nonsteroidal anti-inflammatory drugs
(NSAIDs) have anticolorectal cancer (CRC) activity (Giardiello
et al, 1995). Also, in patients with familial adenomatous polyposis
(FAP), an autosomal dominantly inherited disorder characterised
by the development of numerous colorectal adenomas at a young
age, the NSAIDs sulindac and indomethacin can cause regression
of adenomas (Giardiello et al, 1993; Nugent et al, 1993; Spagnesi
et al, 1994; Hirota et al, 1996; Winde et al, 1997; Picariello et al,
1998). The chemopreventive effect of NSAIDs appears mediated by
the induction of apoptosis and cell cycle arrest (Pasricha et al,
1995; DuBois and Smalley, 1996; Piazza et al, 1997; Keller et al,
1999; Shiff and Rigas, 1999). The molecular mechanisms under-
lying these biological effects are not completely understood.
Nonsteroidal anti-inflammatory drugs inhibit the enzymatic
activity of cyclooxygenase (COX)-1 and -2, enzymes that convert
arachidonic acid into prostaglandins (Shiff and Rigas, 1999).
However, COX-independent mechanisms may also play a role,
since NSAIDs inhibit the growth of colon cancer cell lines lacking
COX-2 expression (Hanif et al, 1996; Zhang et al, 1999; Smith et al,
2000).
Oncogenic activation of the Wnt-signalling pathway by muta-
tions in Adenomatous polyposis coli (APC) or b-catenin, which
results in the accumulation and nuclear translocation of b-catenin
and in b-catenin/TCF4-regulated transcription of TCF target genes,
is mandatory for the initial neoplastic transformation of intestinal
epithelium (reviewed in Kinzler and Vogelstein, 1996; Bienz and
Clevers, 2000). Previous studies have shown an effect of NSAIDs on
the expression and localisation of b-catenin, suggesting nuclear b-
catenin as an alternative target for the chemopreventive effect of
NSAIDs. Nonsteroidal anti-inflammatory drugs were shown to
prevent the nuclear accumulation of b-catenin in chemically
induced colon tumours in rats (Brown et al, 2001) and in human
colorectal cancer cell lines (Smith et al, 2000; Hawcroft et al, 2002).
In addition, indomethacin and aspirin can downregulate the
expression of the TCF target gene cyclin D1 in CRC cell lines
(Dihlmann et al, 2001; Hawcroft et al, 2002). Together, these data
suggest that NSAIDs may exert an antineoplastic effect by
inhibiting the Wnt-signalling pathway. Previously, we reported
low levels of nuclear b-catenin in sulindac-resistant adenomas
(Keller et al, 2001). This could reflect a downregulation of nuclear
b-catenin by sulindac or represent an intrinsic feature of resistant
adenomas. In the present study, we therefore compared nuclear
accumulation of b-catenin in adenomas from FAP patients before
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sand after treatment with sulindac for up to 6 months (Giardiello
et al, 1993). In addition, we studied the effects of the active
metabolite of sulindac, sulindac sulphide, on Wnt-signalling in
human CRC cell lines.
MATERIALS AND METHODS
Patients and adenoma specimens
The study population consisted of five FAP patients who were
treated with sulindac 150mg p.o. twice a day as described
previously (Giardiello et al, 1993, 1996; Cruz-Correa et al, 2002).
All patients had adenomas at the initiation of treatment (baseline)
and showed adenoma regression after 6 months treatment with
sulindac. Patients were selected on the basis of availability of both
adenomas collected at baseline and during the first 6 months of
treatment with sulindac. Patient characteristics are shown in
Table 1. In all, 21 polyps from five patients were studied.
Immunohistochemistry for b-catenin
Immunohistochemistry was performed on 5mm sections of
formalin-fixed, paraffin-embedded samples as described pre-
viously (Entius et al, 2000). For antigen retrieval, the slides were
boiled for 10min in citrate buffer followed by an overnight
incubation at 41C with a primary monoclonal antibody against
b-catenin, clone 14 (Transduction Laboratories, Lexington, KY,
USA). The staining pattern in adjacent normal mucosa was used as
an indication for specificity.
Immunostained slides were scored semiquantitatively using
a scale from 0 to 3 (0: no expression; 1: o5% positive nuclei; 2:
5–25% positive nuclei; 3: 425% positive nuclei). Also, membra-
nous staining was scored separately as normal or decreased in
comparison to adjacent mucosa. Slides were assessed in a coded
manner by two independent observers (JJK and GJAO) and
discrepancies were solved by consensus. Comparisons of staining
patterns between adenomas collected at baseline and during
treatment with sulindac were made using the nonparametric
Mann–Whitney test and Fisher’s exact test. A Po0.05 was
considered statistically significant; P-values were two-sided.
Cell culture and TCF reporter analysis
The human CRC cell lines DLD1 and SW480 were grown in RPMI
medium supplemented with 10% fetal calf serum, 100Uml
 1
penicillin and 100mgml
 1 streptomycin (all from Life Technolo-
gies, Paisley, UK). Colorectal carcinoma cells were transiently
transfected with either 5mg pTOPflash or pFOPflash reporter
plasmids (Upstate Biotechnology, Lake Placid, NY, USA) using
lipofectamine (Invitrogen, Paisley, UK). To correct for differences
in transfection efficiency, cells were cotransfected with a reporter
plasmid containing a GFP gene. Transfection efficiency was
determined in live cells by counting, with a fluorescence
microscope fitted with phase-contrast optics, the number of
GFP-positive cells as well as the total cell number in 10
independent optical fields. The resulting transfection efficiency
was used to correct for differences in transfection in each culture
well in each experiment. All experiments were performed in
triplicate. Cells were grown with or without the addition of
sulindac sulphide (100mM) for 24 or 48h. In addition, cells were
grown with different concentrations of sulindac sulphide (0–
100mM) for 24h. Sulindac is in vivo metabolised into sulindac
sulphide and sulindac sulphone by the intestinal flora. As these
bacteria are not present in in vitro experiments, sulindac cannot be
converted into its active metabolite. Therefore, we used the active
metabolite of sulindac, sulindac sulphide, in our in vitro
experiments. The concentration range of sulindac sulphide in this
study was equivalent to that used by others (Zhang et al, 1999;
Smith et al, 2000; Hawcroft et al, 2002). Sulindac sulphide was
prepared as 1000  stock solution in dimethyl sulphoxide
(DMSO). Control cultures contained DMSO at an equivalent
dilution, resulting in a final DMSO concentration of 0.1%. After the
indicated period of time, cells were counted and equal numbers of
cells were lysed in luciferase reporter lysis buffer (Promega,
Madison, NY, USA). Cell lysates were monitored for luciferase
activity using luciferase assay substrate buffer (Promega, Madison,
NY, USA). Light units were recorded in a luminometer.
Western blot analysis
The CRC cells DLD1 and SW480 were grown with different
concentrations of sulindac sulphide (0–100mM) for 24h. In
addition, cells were grown with or without 100mM sulindac
sulphide for 24 or 48h. Protein extracts were prepared by
resuspending the cells (0.5 10
6 cells grown to subconfluence in
a T25flask) into lysis buffer (10mM Tris pH 8.0; 15mM NaCl; 1%
NP40, 10% glycerol; 0.4mgml
 1 sodium orthovanadate). Protein
extracts (50mg) were separated by SDS–PAGE and blotted onto
immobilon-P transfer membranes (Millipore corp., Bedford, USA)
by tank blotting. Membranes were blocked in Tris-buffered saline
(100mM Tris-HCl pH 7.5; 150mM NaCl) containing 0.1% Tween
(Sigma, St Louis, MO, USA) and 5% nonfat dry milk, probed with
monoclonal antibodies; 8E4 (against nonphosphorylated b-cate-
nin, dilution 1:1000) (Alexis Biochemicals, San Diego, CA, USA)
and AC-15 (against b-actin, dilution 1:3000) (Sigma), or
polyclonal antibodies: H-102 (against b-catenin, dilution
1:1000), C12 (against Met, dilution 1:1000), M-20 (against cyclin
D1, dilution 1:1000) (all Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Proteins were detected with horseradish peroxidase-
conjugated secondary antibodies (Dakopatts, Glostrup, Denmark)
and a standard chemiluminescence Western blotting protocol
(ECL Western blotting, Amersham Pharmacia Biotech Inc.,
Aylesbury, UK). Blots were analysed by densitometry. Intensities
were quantified using NIH Image software (NIH, USA). All signals
were normalised for loading in comparison with the appropriate
b-actin signal.
Table 1 Patient characteristics
Polyp count Polyps studied
Patients Age (years) Sex APC mutation Colectomy/intact colon Baseline 6 months Baseline After sulindac
I 32 F Not tested IRA 19 3
a 21
II 42 F Codon 423 IRA 47 6
a 26
III 52 F Not tested IRA 10 0 3 2
b
IV 25 F Codon 1061 IRA 7 0 1 2
b
V 23 F Segments 2–3
c IRA 10 3 1 1
aComplete response after 10 months treatment with sulindac.
bStudied after 4 months treatment with sulindac.
cAssessed with protein truncation test, mutation between codons
1099 and 1217 (overlapping part of segments 2 and 3 of APC protein). Listed are age, sex, mutational status, surgical status, polyp count before and after 6 months sulindac and
numbers of polyps studied. F¼female; IRA¼ileorectal anastomosis; APC=Adenomatous polyposis coli.
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sRESULTS
b-Catenin expression in adenomas before and after
sulindac treatment
In all, 21 adenomas from FAP patients removed before (n¼9) and
after (n¼12) treatment with sulindac for up to 6 months were
evaluated. The median treatment duration was 3 months with a
range of 2–6 months and a mean of 3.7 months. All adenomas
were tubular or tubulovillous lesions, o1cm, with mild to
moderate dysplasia. No morphological differences were noted
between adenomas removed before and after treatment. The
nuclear accumulation of b-catenin was assessed semiquantitatively
on immunostained slides. Immunostained slides were scored
semiquantitatively as described in the Materials and methods
section and summarised in Table 2. There was significantly
more nuclear accumulation of b-catenin in baseline adenomas
compared to adenomas collected after treatment with sulindac
(Po0.02)(Figure 1). Membranous b-catenin was decreased in nine
out of nine baseline adenomas, and in nine out of 12 adenomas
removed after sulindac (P40.05). In the adjacent mucosa, a
predominantly membranous staining without the nuclear accu-
mulation of b-catenin was always observed.
Sulindac targets b-catenin/TCF-activated transcription
The molecular mechanism of chemopreventive action of sulindac
sulphide was analysed in human colorectal cancer cell lines DLD1
and SW480. These cell lines contain a constitutively activated Wnt-
signalling pathway caused by mutations in the APC gene and are
devoid of COX-2 expression (Boon et al, 2002; and confirmed by
Western blotting, data not shown). The inhibition of b-catenin/
TCF transcriptional activation by sulindac sulphide was monitored
by transfecting a TCF reporter (pTOPflash) or, as a control, a
construct containing scrambled TCF binding sites (pFOPflash) in
both CRC cell lines. Differences in transfection efficiency were
corrected for by cotransfecting the cells with a GFP-encoding
reporter plasmid, as described in the Materials and methods
section. Following sulindac sulphide (100mM) treatment for 24 or
48h, b-catenin/TCF-activated TOPflash activity was abrogated in
both DLD1 and SW480 cells (Figure 2A and B). Comparable results
were observed by indomethacin treatment of the CRC cell lines
(data not shown). The inhibition of TCF-mediated transcription
was also seen after treatment of both cell lines with different
concentrations (0–100mM) of sulindac sulphide (Figure 2C and D).
The effect of sulindac sulphide treatment on b-catenin/TCF-
activated TOPflash activity was already visible after treatment of
the cells with 25mM sulindac sulphide. FOPflash activity remained
unchanged in both cell lines, indicating that sulindac sulphide
treatment inhibited the Wnt-signalling pathway.
To further support this conclusion, we determined the effect of
sulindac sulphide treatment on (i) the phosphorylation status of b-
catenin and on (ii) the expression of TCF target genes. In the
absence of Wnt signalling, b-catenin is phosphorylated by
glycogen synthase kinase-3b (GSK-3b) and targeted for degrada-
tion by the ubiquitin–proteasomal pathway. Mutations in the APC
gene, present in both DLD1 and SW480 cells, lead to a reduced
phosphorylation of b-catenin and to the accumulation of nonphos-
phorylated b-catenin in the nucleus. Following sulindac sulphide
treatment, a decrease in nonphosphorylated b-catenin expression
in both cell lines was noted (Figure 3). Furthermore, the expression
levels of the TCF target genes Met (Boon et al, 2002) and cyclin D1
(Shtutman et al, 1999) were also downregulated in a time- and
dose-dependent manner (Figure 3). A comparable dose- and time-
dependent decrease in nonphosphorylated b-catenin and in the
expression levels of the TCF target genes Met and cyclin D1 was
also noted in response to indomethacin treatment (data not
shown).
DISCUSSION
In addition to COX-2, a number of alternative targets have been
implicated in the chemopreventive action of NSAIDs, including
Bcl-2, NF-kB, NAG-1 and PPARd (Kopp and Ghosh, 1994; He et al,
1999; McEntee et al, 1999; Baek et al, 2001), suggesting that various
distinct molecular pathways may play a role in the antitumour
effects of these drugs. The present study provides in vivo and in
vitro evidence that the b-catenin/TCF-4-signalling pathway is a
target of sulindac.
We observed that the nuclear b-catenin expression in adenomas
of FAP patients treated with sulindac is strongly decreased in
comparison to the b-catenin expression in pretreatment adenomas
Table 2 Nuclear b-catenin expression in adenomas before and after
sulindac treatment
Score
No. of adenomas 0 1 2 3
Before treatment 0 4 1 4
After treatment
* 4620
*P¼0.018.
Figure 1 b-catenin expression in adenomas of FAP patients. Adenomas of FAP patients before (A) and after treatment with sulindac (B) were stained
with an antibody against b-catenin. After sulindac treatment, the nuclear b-catenin staining (arrow) is strongly diminished (arrowhead).
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sof the same patients. A similar decrease in nuclear b-catenin has
also been reported in rodent intestinal tumours (Brown et al,
2001). Previously, we found less nuclear b-catenin in sulindac-
resistant adenomas compared to baseline adenomas (Keller et al,
2001). Those sulindac-resistant adenomas were collected during
treatment with sulindac for up to 4 years, from selected sulindac-
resistant patients, with a median treatment duration of 20 months,
a range of 3–49 months and a mean of 26 months. Therefore, our
previous study could not distinguish whether decreased nuclear b-
catenin was caused by sulindac or reflected intrinsic features of
sulindac-resistant adenomas. The present study compared adeno-
mas from FAP patients removed before and after treatment with
sulindac for up to 6 months. At that time point, the maximum
efficacy of sulindac on the number and size of adenomas was
noted (Giardiello et al, 1993), and in general resistance started
to develop afterwards. Thus, it is assumed that the observed
decrease of nuclear b-catenin in the present investigation is
mostly accounted for by the sulindac treatment, instead of
being related to resistance. This corresponds to data from McEntee
et al (1999) showing decreased nuclear and cytoplasmic b-catenin
in adenomas of Apc
Min mice upon treatment with sulindac for
several days.
The observation that sulindac treatment leads to a decrease in
nuclear b-catenin in vivo is of great interest, since it suggests a
direct link between the tumour suppressive effects of sulindac and
the key defect of colorectal cancer, that is, deregulated Wnt
signalling. Mutations involving components of the Wnt-signalling
cascade, specifically in APC or b-catenin, are essential for the
initiation of colorectal cancer. In the normal intestinal epithelium,
these molecules are part of a multiprotein complex. In this
complex, b-catenin is phosphorylated by GSK-3b and targeted for
degradation by the ubiquitin–proteasomal pathway. Mutations in
APC or b-catenin lead to dissociation of the complex, causing the
accumulation of nonphosphorylated b-catenin, which translocates
to the nucleus and acts as a transcriptional coactivator of TCF
transcription factors (Kinzler and Vogelstein, 1996; Bienz and
Clevers, 2000). Our observation that sulindac treatment diminishes
the nuclear accumulation of the transcriptional coactivator b-
catenin in adenomas of FAP patients in vivo strongly suggests that
NSAIDs exert tumour suppressive effects by interfering with TCF-
mediated transcription. In line with these in vivo data, we observed
that sulindac sulphide treatment of the CRC cell lines DLD1 and
SW480 strongly suppresses TCF reporter activity. Furthermore,
NSAID treatment decreased the expression of the TCF target genes
Met and cyclin D1 in a time- and dose-dependent manner. These
suppressive effects were not due to a generalised transcriptional
repression, since FOPflash reporter activities remained unchanged
after sulindac sulphide treatment in the CRC cells. The effect of
NSAIDs is less pronounced on the TCF-target protein levels than
on TCF-regulated transcription, as shown in the TCF reporter
assay. This effect can be explained by slow protein turnover rates.
Sulindac sulphide treatment led to only a moderate decrease in
total b-catenin levels. This finding was recently also reported by
Smith et al (2000), although Dihlmann et al (2001) reported no
appreciable effect on b-catenin levels, despite the change in TCF-
mediated transcription. Although we have no explanation for this
discrepancy, the validity of our finding is strongly supported by
the observation that the decrease in nonphosphorylated b-catenin
(which represents the transcriptionally active portion of b-catenin)
was more pronounced than that of the total b-catenin pool,
suggesting a selective effect of sulindac sulphide on the pool of b-
catenin that is involved in Wnt signalling. Since the CRC cells used
in this study carry an APC mutation, preventing the formation of
the APC/b-catenin multiprotein complex, it seems unlikely that the
NSAID-induced decrease in nonphosphorylated b-catenin is
regulated by GSK-3b activity. Other pathways of b-catenin
downregulation might involve caspase-mediated cleavage (Schmei-
ser et al, 1998) or the inhibition of guanosine 30,50-cyclic
monophosphate (cGMP) phosphodiesterase, leading to increased
cGMP levels and downregulation of b-catenin, possibly via protein
kinase G phosphorylation (Thompson et al, 2000). Also, NSAIDs
may directly inhibit the translocation of b-catenin to the nucleus.
Taken together, our findings demonstrate that sulindac
suppresses TCF-mediated transcription, presumably by preventing
the nuclear accumulation of active b-catenin. Our observations
provide new insights in the pathways involved in chemoprevention
of NSAIDs and could advance the design of better chemopreven-
tive drugs.
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Figure 2 TCF reporter activity following sulindac treatment of DLD1 and SW480 cells. DLD1 (A) or SW480 cells (B) were treated with 100mM sulindac
sulphide for 24 or 48h. In parallel, DLD1 (C) or SW480 (D) cells were treated with various concentrations of sulindac sulphide (0–100mM) for 24h. Cells
were lysed and TOPflash and FOPflash activities were recorded in a luminometer.
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Figure 3 Kinetics of the effect of sulindac on TCF-regulated target genes. DLD1 (A) or SW480 cells (B) were treated with various concentrations of
sulindac sulphide (0–100mM) for 24h. Protein lysates were prepared and Western blot analyses performed with antibodies recognising total b-catenin,
nonphosphorylated b-catenin, Met and cyclin D1. Blots were analysed by densitometry and each signal was normalised for loading in comparison with the
appropriate b-actin signal (C). Data shown are mean values7s.e.m. from three independent experiments. In parallel, DLD1 or SW480 cells were treated
with sulindac sulphide (100mM) for 24 or 48h (D).
Sulindac targets Wnt signalling
EMJ Boon et al
228
British Journal of Cancer (2004) 90(1), 224–229 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sREFERENCES
Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE (2001) Cyclooxygenase
inhibitors regulate the expression of a TGF-beta superfamily member
that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59:
901–908
Bienz M, Clevers H (2000) Linking colorectal cancer to Wnt signaling. Cell
103: 311–320
Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST (2002)
Wnt signaling regulates expression of the receptor tyrosine kinase met in
colorectal cancer. Cancer Res 62: 5126–5128
Brown WA, Skinner SA, Vogiagis D, O’Brien PE (2001) Inhibition of beta-
catenin translocation in rodent colorectal tumors: a novel explanation for
the protective effect of nonsteroidal antiinflammatory drugs in colorectal
cancer. Dig Dis Sci 46: 2314–2321
Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM (2002)
Long-term treatment with sulindac in familial adenomatous polyposis: a
prospective cohort study. Gastroenterology 122: 641–645
Dihlmann S, Siermann A, von Knebel Doeberitz M (2001) The nonsteroidal
anti-inflammatory drugs aspirin and indomethacin attenuate beta-
catenin/TCF-4 signaling. Oncogene 20: 645–653
DuBois RN, Smalley WE (1996) Cyclooxygenase, NSAIDs, and colorectal
cancer. J Gastroenterology 31: 898–906
Entius MM, Keller JJ, Drillenburg P, Kuypers KC, Giardiello FM, Offerhaus
GJ (2000) Microsatellite instability and expression of hMLH-1 and
hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre
syndrome. Clin Cancer Res 6: 1784–1789
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P,
Booker SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and
rectal adenomas with sulindac in familial adenomatous polyposis. N Engl
J Med 328: 1313–1316
Giardiello FM, Offerhaus GJ, DuBois RN (1995) The role of nonsteroidal
anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer
31A: 1071–1076
Giardiello FM, Offerhaus JA, Tersmette AC, Hylind LM, Krush AJ,
Brensinger JD, Booker SV, Hamilton SR (1996) Sulindac induced
regression of colorectal adenomas in familial adenomatous polyposis:
evaluation of predictive factors. Gut 38: 578–581
Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI,
Rigas B (1996) Effects of nonsteroidal anti-inflammatory drugs on
proliferation and on induction of apoptosis in colon cancer cells by a
prostaglandin-independent pathway. Biochem Pharmacol 52: 237–245
Hawcroft G, D’Amico M, Albanese C, Markham AF, Pestell RG, Hull MA
(2002) Indomethacin induces differential expression of beta-catenin,
gamma-catenin and T-cell factor target genes in human colorectal cancer
cells. Carcinogenesis 23: 107–114
He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARdelta is an
APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:
335–345
Hirota C, Iida M, Aoyagi K, Matsumoto T, Tada S, Yao T, Fujishima M
(1996) Effect of indomethacin suppositories on rectal polyposis in
patients with familial adenomatous polyposis. Cancer 78: 1660–1665
Keller JJ, Offerhaus GJ, Drillenburg P, Caspers E, Musler A, Ristimaki A,
Giardiello FM (2001) Molecular analysis of sulindac-resistant adenomas
in familial adenomatous polyposis. Clin Cancer Res 7: 4000–4007
Keller JJ, Offerhaus GJ, Polak M, Goodman SN, Zahurak ML, Hylind LM,
Hamilton SR, Giardiello FM (1999) Rectal epithelial apoptosis in familial
adenomatous polyposis patients treated with sulindac. Gut 45: 822–828
Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer.
Cell 87: 159–170
Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and
aspirin. Science 265: 956–959
McEntee MF, Chiu CH, Whelan J (1999) Relationship of beta-catenin and
Bcl-2 expression to sulindac-induced regression of intestinal tumors in
Min mice. Carcinogenesis 20: 635–640
Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK (1993)
Randomized controlled trial of the effect of sulindac on duodenal and
rectal polyposis and cell proliferation in patients with familial
adenomatous polyposis. Br J Surg 80: 1618–1619
Pasricha PJ, Bedi A, O’Connor K, Rashid A, Akhtar AJ, Zahurak ML,
Piantadosi S, Hamilton SR, Giardiello FM (1995) The effects of sulindac
on colorectal proliferation and apoptosis in familial adenomatous
polyposis. Gastroenterology 109: 994–998
Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R,
Ahnen DJ (1997) Apoptosis primarily accounts for the growth-inhibitory
properties of sulindac metabolites and involves a mechanism that is
independent of cyclooxygenase inhibition, cell cycle arrest, and p53
induction. Cancer Res 57: 2452–2459
Picariello L, Brandi ML, Formigli L, Orlandini SZ, Dolara P, Caderni G,
Raimondi L, Tonelli F (1998) Apoptosis induced by sulindac sulfide in
epithelial and mesenchymal cells from human abdominal neoplasms. Eur
J Pharmacol 360: 105–112
Schmeiser K, Hammond EM, Roberts S, Grand RJ (1998) Specific cleavage
of gamma catenin by caspases during apoptosis. FEBS Lett 433: 51–57
Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the
antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs).
J Exp Med 190: 445–450
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R,
Ben-Ze’ev A (1999) The cyclin D1 gene is a target of the beta-catenin/
LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522–5527
Smith ML, Hawcroft G, Hull MA (2000) The effect of non-steroidal anti-
inflammatory drugs on human colorectal cancer cells: evidence of
different mechanisms of action. Eur J Cancer 36: 664–674
Spagnesi MT, Tonelli F, Dolara P, Caderni G, Valanzano R, Anastasi A,
Bianchini F (1994) Rectal proliferation and polyp occurrence in patients
with familial adenomatous polyposis after sulindac treatment. Gastro-
enterology 106: 362–366
Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D,
Pamukcu R (2000) Exisulind induction of apoptosis involves guanosine
30,50-cyclic monophosphate phosphodiesterase inhibition, protein kinase
G activation, and attenuated beta-catenin. Cancer Res 60: 3338–3342
Winde G, Schmid KW, Brandt B, Muller O, Osswald H (1997) Clinical and
genomic influence of sulindac on rectal mucosa in familial adenomatous
polyposis. Dis Colon Rectum 40: 1156–1168 discussion 1168-9
Zhang X, Morham SG, Langenbach R, Young DA. (1999) Malignant
transformation and antineoplastic actions of nonsteroidal antiinflamma-
tory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp
Med 190: 451–459
Sulindac targets Wnt signalling
EMJ Boon et al
229
British Journal of Cancer (2004) 90(1), 224–229 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s